{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T17:19:40Z","timestamp":1778692780824,"version":"3.51.4"},"reference-count":46,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:00:00Z","timestamp":1778630400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background\/Objectives: This study aimed to determine the incidence of herpes zoster (HZ) and risk factors associated with its occurrence in patients receiving Janus kinase inhibitors (JAKis) for immune-mediated inflammatory diseases (IMIDs), while evaluating preventive strategies and zoster vaccine uptake. Methods: We conducted a retrospective single-center cohort study including patients with rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, inflammatory bowel disease, atopic dermatitis and alopecia areata treated with upadacitinib, baricitinib or tofacitinib. The primary outcome was incident HZ during JAKi exposure. Incidence rates (IRs) were calculated per 100 person-years (PY) and Cox regression identified factors associated with HZ. Results: A total of 292 patients contributed 565.5 PY of JAKi exposure. During follow-up, 23 patients (7.9%) developed HZ, corresponding to an overall IR of 4.07\/100 PY (95% CI 2.40\u20135.73). Incidence rates were numerically lower with upadacitinib and varied across disease groups; differences were not statistically significant. Diabetes mellitus (HR 3.05, 95% CI 1.28\u20137.29) and chronic kidney disease (HR 3.24, 95% CI 1.17\u20138.95) were independently associated with HZ. Herpes simplex infection requiring systemic antiviral therapy was more frequent among patients who developed HZ. Recombinant zoster vaccine (RZV) uptake was low (9.9%), but higher among patients evaluated in a dedicated infectious risk consultation. No HZ events were observed among RZV-vaccinated patients. Although six HZ events (26.1%) were severe, all cases resolved completely. Conclusions: HZ remains a relevant complication of JAKi therapy across IMIDs. Diabetes mellitus and chronic kidney disease may help identify higher-risk patients, while structured infectious risk assessment could improve vaccine uptake.<\/jats:p>","DOI":"10.3390\/jcm15103733","type":"journal-article","created":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T16:26:37Z","timestamp":1778689597000},"page":"3733","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Herpes Zoster in Patients Treated with JAK Inhibitors for Immune-Mediated Inflammatory Diseases: Incidence, Associated Factors and Vaccination Uptake in a Real-World Cohort"],"prefix":"10.3390","volume":"15","author":[{"given":"Ant\u00f3nio","family":"Parch\u00e3o","sequence":"first","affiliation":[{"name":"Faculty of Medicine, University of Porto, Alameda Prof. Hern\u00e2ni Monteiro, 4200-319 Porto, Portugal"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolina","family":"Monteiro","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Porto, Alameda Prof. Hern\u00e2ni Monteiro, 4200-319 Porto, Portugal"},{"name":"Infectious Diseases Department, Unidade Local de Sa\u00fade S\u00e3o Jo\u00e3o, Alameda Prof. Hern\u00e2ni Monteiro, 4200-319 Porto, Portugal"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonardo","family":"Ara\u00fajo-Andrade","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Porto, Alameda Prof. Hern\u00e2ni Monteiro, 4200-319 Porto, Portugal"},{"name":"Infectious Diseases Department, Unidade Local de Sa\u00fade S\u00e3o Jo\u00e3o, Alameda Prof. Hern\u00e2ni Monteiro, 4200-319 Porto, Portugal"},{"name":"NeuroGen Research Group, Center for Health Technology and Services Research (CINTESIS), Rua Dr. Pl\u00e1cido da Costa, 4200-450 Porto, Portugal"},{"name":"RISE-Health, Unit of Anatomy, Department of Biomedicine, Faculty of Medicine, University of Porto, Alameda Prof. Hern\u00e2ni Monteiro, 4200-319 Porto, Portugal"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9356-3272","authenticated-orcid":false,"given":"Cl\u00e1udia Camila","family":"Dias","sequence":"additional","affiliation":[{"name":"Knowledge Management Unit, Department of Community Medicine, Information and Health Decision Sciences, Faculty of Medicine, University of Porto, Alameda Prof. Hern\u00e2ni Monteiro, 4200-319 Porto, Portugal"},{"name":"RISE-Health, Department of Community Medicine, Information and Health Decision Sciences, Faculty of Medicine of the University of Porto, Alameda Prof. Hern\u00e2ni Monteiro, 4200-319 Porto, Portugal"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C\u00e2ndida","family":"Abreu","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Porto, Alameda Prof. Hern\u00e2ni Monteiro, 4200-319 Porto, Portugal"},{"name":"Infectious Diseases Department, Unidade Local de Sa\u00fade S\u00e3o Jo\u00e3o, Alameda Prof. Hern\u00e2ni Monteiro, 4200-319 Porto, Portugal"},{"name":"RISE-Health, Department of Medicine, Faculty of Medicine, University of Porto, Alameda Prof. Hern\u00e2ni Monteiro, 4200-319 Porto, Portugal"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,5,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.revmed.2024.10.452","article-title":"JAK inhibitors (JAKi): Mechanisms of action and perspectives in systemic and autoimmune diseases","volume":"46","author":"Chikhoune","year":"2025","journal-title":"Rev. M\u00e9decine Interne"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/bs.adgen.2025.11.008","article-title":"The JAK-STAT signaling pathway in inflammatory and autoimmune diseases: Its potential role as a therapeutic target","volume":"115","author":"Gundogdu","year":"2026","journal-title":"Adv. Genet."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1093\/ibd\/izab037","article-title":"Hit the Road JAK! The Role of New Oral Treatment in Inflammatory Bowel Disease","volume":"27","author":"Garrido","year":"2021","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"152120","DOI":"10.1016\/j.semarthrit.2022.152120","article-title":"Opportunistic infections associated with Janus kinase inhibitor treatment for rheumatoid arthritis: A structured literature review","volume":"58","author":"Winthrop","year":"2023","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"ii24","DOI":"10.1093\/rheumatology\/keaa895","article-title":"The safety of JAK-1 inhibitors","volume":"60","author":"Clarke","year":"2021","journal-title":"Rheumatology"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jdin.2024.09.012","article-title":"Risk of infections during treatment with oral Janus kinase inhibitors in randomized placebo-controlled trials: A systematic review and meta-analysis","volume":"18","author":"Isufi","year":"2025","journal-title":"JAAD Int."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"15","DOI":"10.2147\/PI.S56313","article-title":"Herpes zoster vaccination in the elderly subjects: Improving awareness and uptake","volume":"2015","author":"Gabutti","year":"2015","journal-title":"Patient Intell."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.mcna.2013.02.002","article-title":"Herpes Zoster","volume":"97","author":"Paauw","year":"2013","journal-title":"Med. Clin. N. Am."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Lupoae, M., B\u0103l\u0103nescu, F., Dumitru, C.N., Nechita, A., Matei, M.N., \u0218tefan, S.C., Lauren\u021biu Tatu, A., Niculet, E., Dumitru, A.O., and Lupoae, A. (2026). Predictors of Severe Herpes Zoster: Contributions of Immunosenescence, Metabolic Risk, and Lifestyle Behaviors. Diseases, 14.","DOI":"10.3390\/diseases14010026"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1177\/2051013615599151","article-title":"Herpes zoster epidemiology, management, and disease and economic burden in Europe: A multidisciplinary perspective","volume":"3","author":"Johnson","year":"2015","journal-title":"Ther. Adv. Vaccines"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1007\/s40121-024-00963-w","article-title":"Systematic Literature Review on the Incidence of Herpes Zoster in Populations at Increased Risk of Disease in the EU\/EEA, Switzerland, and the UK","volume":"13","author":"Marijam","year":"2024","journal-title":"Infect. Dis. Ther."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1136\/annrheumdis-2024-eular.6038","article-title":"POS0454 Janus kinase inhibitors (JAKi) significantly impair signal transducer and activator of transcription (STAT) signaling of varicella-zoster virus (VZV)-specific T-cell memory responses","volume":"83","author":"Almanzar","year":"2024","journal-title":"Ann. Rheum. Dis."},{"key":"ref_13","first-page":"1432","article-title":"Herpes zoster and Janus kinase inhibition in rheumatology and gastroenterology patients: Managing risk and vaccination","volume":"40","author":"Galloway","year":"2022","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2928433","DOI":"10.1155\/dth\/2928433","article-title":"Risk of Herpes Zoster With Janus Kinase Inhibitors Across Disease Indications: A Systematic Review and Network Meta-Analysis","volume":"2025","author":"Lin","year":"2025","journal-title":"Dermatol. Ther."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Cito, A., Fornaro, M., Carenza, A., Anelli, M.G., Scioscia, C., Iannone, F., and Lopalco, G. (2024). Turning the Tide against Herpes Zoster in Rheumatoid Arthritis Patients Treated with JAK Inhibitors. J. Clin. Med., 13.","DOI":"10.3390\/jcm13154423"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1111\/apt.17379","article-title":"Systematic review with network meta-analysis: Risk of Herpes zoster with biological therapies and small molecules in inflammatory bowel disease","volume":"57","author":"Din","year":"2023","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s00296-022-05270-6","article-title":"Herpes zoster in patients with inflammatory arthritides or ulcerative colitis treated with tofacitinib, baricitinib or upadacitinib: A systematic review of clinical trials and real-world studies","volume":"43","author":"Gialouri","year":"2023","journal-title":"Rheumatol. Int."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1136\/annrheumdis-2021-220822","article-title":"Incidence and risk factors for herpes zoster in patients with rheumatoid arthritis receiving upadacitinib: A pooled analysis of six phase III clinical trials","volume":"81","author":"Winthrop","year":"2022","journal-title":"Ann. Rheum. Dis."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1136\/annrheumdis-2016-209131","article-title":"Real-world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritis","volume":"75","author":"Curtis","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1007\/s10067-024-07041-z","article-title":"Prior herpes zoster occurrence and high-dose corticosteroids increase herpes zoster risk in rheumatoid arthritis patients receiving janus kinase inhibitors in a retrospective and observational study","volume":"43","author":"Chen","year":"2024","journal-title":"Clin. Rheumatol."},{"key":"ref_21","first-page":"571893","article-title":"Herpes Zoster Risk in Rheumatoid Arthritis Patients on Janus Kinase Inhibitors: A 17-Year Experience from Rheumatoid Arthritis Saudi Database (RASD)","volume":"18","author":"Abudaowd","year":"2026","journal-title":"Open Access Rheumatol."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Xu, Q., He, L., and Yin, Y. (2023). Risk of herpes zoster associated with JAK inhibitors in immune-mediated inflammatory diseases: A systematic review and network meta-analysis. Front. Pharmacol., 14.","DOI":"10.3389\/fphar.2023.1241954"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2445384","DOI":"10.1080\/21645515.2024.2445384","article-title":"Current status of immunisation for herpes zoster","volume":"21","author":"Cunningham","year":"2025","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"rkae127","DOI":"10.1093\/rap\/rkae127","article-title":"The relationship between Zoster serology, vaccination uptake and infection rates: A single-centre cross-sectional study","volume":"8","author":"Ahmed","year":"2024","journal-title":"Rheumatol. Adv. Pract."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Regazzi, L., Martinelli, S., Rizzo, F., Tamburrini, E., Salvo, P.F., Bosello, S.L., Landi, F., Sica, S., Spadea, A., and Pascucci, D. (2025). Understanding Attitudes Toward Zoster Vaccination in the Hospital Setting: A Multidisciplinary Model to Contrast Vaccine Hesitancy in Fragile Patients\u2014A Prospective Longitudinal Observational Study. Vaccines, 13.","DOI":"10.3390\/vaccines13080843"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Chiavarini, M., Bechini, A., Boccalini, S., Barash, A., Castellana, E., Senape, A., and Bonanni, P. (2025). Vaccination Against Herpes Zoster in Adults: Current Strategies in European Union Countries. Vaccines, 13.","DOI":"10.3390\/vaccines13101073"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Yoshida, S., Miyata, M., Suzuki, E., Kanno, T., Sumichika, Y., Saito, K., Matsumoto, H., Temmoku, J., Fujita, Y., and Matsuoka, N. (2024). Incidence Rates of Infections in Rheumatoid Arthritis Patients Treated with Janus Kinase or Interleukin-6 Inhibitors: Results of a Retrospective, Multicenter Cohort Study. J. Clin. Med., 13.","DOI":"10.3390\/jcm13103000"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1111\/jdv.20674","article-title":"Infection risk in atopic dermatitis patients treated with biologics and JAK inhibitors: BioDay results","volume":"39","author":"Atash","year":"2025","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1759720x20936059","DOI":"10.1177\/1759720X20936059","article-title":"JAK inhibitors and infections risk: Focus on herpes zoster","volume":"12","author":"Sunzini","year":"2020","journal-title":"Ther. Adv. Musculoskelet. Dis."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1007\/s40744-024-00694-x","article-title":"Safety and Efficacy of Upadacitinib in Patients with Rheumatoid Arthritis Refractory to Biologic DMARDs: Results Through Week 216 from the SELECT-CHOICE Study","volume":"11","author":"Kato","year":"2024","journal-title":"Rheumatol. Ther."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1002\/art.39670","article-title":"Risk of Herpes Zoster in Autoimmune and Inflammatory Diseases: Implications for Vaccination","volume":"68","author":"Yun","year":"2016","journal-title":"Arthritis Rheumatol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"72","DOI":"10.5114\/ada.2023.135764","article-title":"Systematic review and network meta-analysis of the risk of Herpes zoster with biological therapies and selective Janus kinase-1 inhibitors in atopic dermatitis","volume":"41","author":"Manzar","year":"2024","journal-title":"Post\u0119py Dermatol. Alergol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.reuma.2021.06.004","article-title":"JAK kinase inhibitors and varicella-zoster virus infection in patients with rheumatoid arthritis: A systematic review of the literature","volume":"18","year":"2022","journal-title":"Reumatol. Clin."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Espi, M., Koppe, L., Fouque, D., and Thaunat, O. (2020). Chronic Kidney Disease-Associated Immune Dysfunctions: Impact of Protein-Bound Uremic Retention Solutes on Immune Cells. Toxins, 12.","DOI":"10.3390\/toxins12050300"},{"key":"ref_35","first-page":"103510","article-title":"Immune cell dysfunction: A critical player in development of diabetes complications","volume":"73","author":"Saadh","year":"2025","journal-title":"Curr. Res. Transl. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s13300-018-0394-4","article-title":"Herpes Zoster and Diabetes Mellitus: A Review","volume":"9","author":"Papagianni","year":"2018","journal-title":"Diabetes Ther."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1210\/clinem\/dgab675","article-title":"Association Between Diabetes Mellitus and the Risk of Herpes Zoster: A Systematic Review and Meta-analysis","volume":"107","author":"Huang","year":"2022","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1053\/j.ajkd.2012.03.018","article-title":"Risk of herpes zoster in CKD: A matched-cohort study based on administrative data","volume":"60","author":"Wu","year":"2012","journal-title":"Am. J. Kidney Dis."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1016\/j.ekir.2021.02.024","article-title":"Systematic Review and Meta-analysis of Herpes Zoster Vaccine in Patients With CKD","volume":"6","author":"Hamad","year":"2021","journal-title":"Kidney Int. Rep."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/ijd.17501","article-title":"Infection risk with JAK inhibitors in dermatoses: A meta-analysis","volume":"64","author":"Ireland","year":"2025","journal-title":"Int. J. Dermatol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"152362","DOI":"10.1016\/j.semarthrit.2024.152362","article-title":"Continued JAK inhibitor treatment on the risk of recurrent herpes zoster reactivation in patients with immune-mediated inflammatory diseases: A nationwide population-based study in South Korea","volume":"65","author":"Kim","year":"2024","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"80","DOI":"10.15585\/mmwr.mm7103a2","article-title":"Use of Recombinant Zoster Vaccine in Immunocompromised Adults Aged \u226519 Years: Recommendations of the Advisory Committee on Immunization Practices\u2014United States, 2022","volume":"71","author":"Anderson","year":"2022","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"6015","DOI":"10.1016\/j.vaccine.2021.08.073","article-title":"Standardizing shared vaccination responsibilities among specialists to improve vaccination rates of immunosuppressed patients","volume":"39","author":"Bhat","year":"2021","journal-title":"Vaccine"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Marra, F., Yip, M., Cragg, J.J., and Vadlamudi, N.K. (2024). Systematic review and meta-analysis of recombinant herpes zoster vaccine in immunocompromised populations. PLoS ONE, 19.","DOI":"10.1371\/journal.pone.0313889"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1093\/ibd\/izac063","article-title":"Long-term Risk of Herpes Zoster Infection in Patients With Ulcerative Colitis Receiving Tofacitinib","volume":"29","author":"Winthrop","year":"2023","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Mattei, A., Cialfi, D., D\u2019Annunzio, A., Fabiani, L., Fiasca, F., and Gabutti, G. (2025). Comorbidities in hospitalized patients with herpes zoster: An Italian retrospective observational study in the years 2011\u20132023. BMC Infect. Dis., 26.","DOI":"10.1186\/s12879-025-12319-x"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/10\/3733\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T16:50:42Z","timestamp":1778691042000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/10\/3733"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,13]]},"references-count":46,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["jcm15103733"],"URL":"https:\/\/doi.org\/10.3390\/jcm15103733","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,13]]}}}